 U.S.-listed shares of AstraZeneca AZN, 2.98 were up 2.5 in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. IONS, 5.54 ; shares in Ionis were up 5.1 on Tuesday. 